• About Optos
  • Company Information
  • Investor Relations
  • Corporate Releases
  • Glossary of Technical Terms
  • Corporate Social Responsibility
  • Careers
  • Newsroom
• Your Eye Health
  • Eye Care and Vision protection
  • Conditions of the Retina
  • FAQs
  • Eye Health Resource Links
  • Patient Testimonials about optomap®
  • Patient Testimonials about optomap®
• Contact Optos
  • Worldwide Locations
  • Investor Email alert
• optos Deutschland
  • Wir über uns
  • Ich bin Arzt
  • Ich bin Patient
  • Ich bin Journalist
  • Wo finde ich optomap® Anwender
  • U-Revu Software Herunterladen

• Company Information
• Investor Relations
  • Advisers
  • Annual General Meeting
  • Analyst Coverage
  • Announcements
  • Annual Information Updates
  • Corporate Governance
  • Email alert
  • Financial Calendar
  • Financial Information
  • Investor Contact
  • Presentations
  • Share Price
  • Share Price Graph
• Corporate Releases
• Glossary of Technical Terms
• Corporate Social Responsibility
• Careers
• Newsroom

Board of Directors

Dr John M. Padfield, Non-executive Chairman

John Padfield joined the company as a non-executive director in November 2005 and was appointed Chairman of the board of directors in January 2006. Dr Padfield has been an executive director and non-executive director of a number of public and private companies in Europe, the United States and Japan and is currently Chairman of NextPharma Technologies Holdings Ltd and Cambridge Laboratories Ltd. From 1999 to 2002, Dr Padfield was Chief Executive Officer of Amersham Health and a director of Amersham plc, and from 1994 to 1999 he was Chief Executive Officer of Chiroscience Group plc. His experience includes 28 years working in the pharmaceutical, biotechnology and diagnostic imaging industries, including Glaxo Manufacturing Services between 1990 and 1994 and Glaxo Group Research between 1979 and 1990. Dr Padfield holds a Doctor of Philosophy and a Bachelor of Pharmacy degree from the University of Nottingham.

Tom Butts, Chief Executive Officer

Tom Butts joined the Company as Chief Executive Officer in December 2006 and is responsible for the overall leadership and direction of the Company. Mr Butts has over twenty years of progressively senior international-level experience within the healthcare sector. Most recently he was the President and Chief Operating Officer of IDX Systems Corporation, a public healthcare information technology company with $600 million in annual sales, which he oversaw before it was subsequently acquired by GE Healthcare for $1.5 billion earlier this year. Mr Butts led the successful expansion of the IDX business achieving over $200 million in growth. Prior to his appointment to this position in January 2004 he was President and General Manager of IDX Flowcast, the largest operating unit, a position he held since January 2002. Prior to joining IDX Mr Butts spent 17 years with GE Healthcare, where he held a number of leadership positions in sales and marketing. Mr Butts holds a degree in Business Administration from Western New England College.

Allan Watson, Chief Financial Officer

Allan Watson is Chief Financial Officer and Company Secretary. Mr Watson joined Optos in December 2003 and is responsible for the overall financial management and direction of the company. Between late 2000 and 2003, Mr Watson was part of the senior management team at uDate.com Inc, a US publicly listed internet business. Between 1998 and 2000 Mr Watson was a member of the corporate finance team at Williams Holdings plc, working on transactions in Europe, North America, South America and in Africa. Previously, between 1990 and 1998 he was with Reckitt & Colman plc in various financial roles throughout the UK and in France. Mr Watson is a professionally qualified accountant, member of the Chartered Institute of Management Accountants and also holds an honors B.Sc. in Pharmacy from the Robert Gordons University in Aberdeen.

Douglas C. Anderson, Executive Director

Douglas Anderson founded the company in 1992 and is an executive director. Mr Anderson is the Chairman of Crombie Anderson Associates Ltd., a multi‑disciplinary design consulting firm specialising in technology-based product development, and is the former Director of Creos International plc. He has held previous positions with Fortronic Limited and Aberglen Industrial Design, a division of Aberglen Holdings Limited. Mr Anderson holds a Higher National Diploma in Industrial Design (Engineering) from Napier University in Edinburgh and is a member of The Association for Research in Vision and Ophthalmology (ARVO), Bethesda.

Patrick R. D. Paul, Non-executive Director

Patrick Paul has served as a director since 1996, and has over 25 years of experience in the medical device industry gained in North America and in Europe. In 1975 Mr Paul co‑founded Support Systems International, SA and he later became the Chairman and Chief Executive Officer of Support Systems International Inc., which became the holding company of the Support System group, before its eventual sale to Hillenbrand Industries, Inc. He is Chairman of the Tissue Science Laboratories Limited plc and of Vertical Asset Management Limited and a fellow of the Institute of Chartered Accountants in England and Wales. Mr Paul has a degree in Engineering from the University of Southampton and is a professionally qualified accountant.

Anne M. Glover, Non-executive Director

Anne Glover has been a director since 1996. She is co-founder and Chief Executive of Amadeus Capital Partners Limited, a UK-based venture capital fund. Her background in venture capital includes positions with Apax Partners & Company Ventures and later Calderstone Capital. Previously, she served as Chief Operating Officer with the Virtuality Group plc and has worked with Cummins Engine and Bain & Co in Boston. She holds an M.A. in Metallurgy and Materials Science from Clare College, Cambridge and a Master’s in Public and Private Management from Yale School of Management.

Barry M. Rose, Non-executive Director

Barry Rose joined the company as a non-executive director in December 2005, and serves as the Senior Independent Director to the Board. Mr Rose was Chief Executive of Scottish Provident UK from 1993 to 2001. Prior to his appointment as Chief Executive of Scottish Provident UK he was head of Investments at Scottish Provident Institution backed up by more than 27 years’ investment experience. Mr Rose is also a non-executive director of Liverpool Victoria Friendly Society, Wolfson Microelectronics plc and Baillie Gifford Shin Nippon plc. Mr Rose has an Honors degree in Mathematics from Manchester University.

David R. Guyer, M.D., Non-executive Director

David Guyer joined the company as a non-executive Director in May 2006. Dr Guyer is a Consultant to management and the Board of OSI Pharmaceuticals (NASDAQ:OSIP), where he provides specialist input in ophthalmology and retinal disease and is a Venture Partner of SV Life Sciences Advisers LLC (SVLS). Previously, he was Executive Vice President of OSI Pharmaceuticals and Chief Executive Officer of (OSI) Eyetech, the biopharmaceutical business unit of OSI that specialised in the development and commercialisation of novel therapeutics to treat diseases of the eye, which he co-founded prior to its acquisition by OSI. Dr Guyer is an internationally recognised authority on macular diseases, particularly the use of anti-angiogenic drugs for the treatment of AMD and Diabetic Macular Edema (DME).  He received his M.D. from the Johns Hopkins University School of Medicine and his undergraduate degree from Yale College.

Saad H. Hammad, Non-executive Director

Mr Hammad joined the company as a non-executive director in August 2007 and serves on the Remuneration Committee. Mr Hammad is Chief Commercial Officer of easyJet plc, one of the largest airlines in Europe. Prior to joining easyJet plc in November 2005, Mr Hammad was Managing Director (Europe) at Tibbett & Britten, a third party logistics provider, where he managed the outsourced supply chain operations across Europe of manufacturers and retailers that included P&G, Unilever, PepsiCo, Tesco, Wal-Mart, Carrefour and Metro. Previously, Mr Hammad was CEO of Autocascade, a pan-European web-based yield management company and before that was responsible for the worldwide commercial operation of 3,710 stores at Minit, a multi-service retailer. Mr Hammad has also held roles in consumer retailing and brand management at Vision Express, Thorn EMI and Procter & Gamble. Mr Hammad holds an undergraduate degree from Oxford University and an MBA from INSEAD.

Rosalyn S. Wilton, Non-executive Director

Ms Wilton joined the company as a non-executive director in August 2007 and serves as Chairman of the Remuneration Committee. Ms Wilton is Chairman of Ipreo Holdings LLC, the US-based financial data and solutions group, which was formed following the merger of i-Deal LLC and Hemscott Group Ltd and the acquisition of Marketpipe. Before the merger, Ms Wilton was Chief Executive Officer of Hemscott plc. Ms Wilton has previously served as Managing Director, Reuters Information Services, Managing Director, Reuters Transactions Products and as a member of the Reuters Executive Committee. Ms Wilton has held non-executive directorship positions with Scottish Widows and The London International Financial Futures Exchange. Ms Wilton holds a B.Sc (Hons) from the University of London.